Zhongzhi Pharmaceutical Holdings Limited provided unaudited consolidated earnings guidance for the year ended 31 December 2017. For the year, the Group is expected to record a significant increase of approximately over 25% in net profit for the year ended 31 December 2017 as compared with that of the corresponding period in 2016. Such expected increase is mainly due to the significant increase in the sales of modern Chinese medicine decoction pieces -- Caojinghua cell wall broken herbs.